| Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants A Galanis, H Ma, T Rajkhowa, A Ramachandran, D Small, J Cortes, ... Blood, The Journal of the American Society of Hematology 123 (1), 94-100, 2014 | 297 | 2014 |
| Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors MC Heinrich, D Griffith, A McKinley, J Patterson, A Presnell, ... Clinical cancer research 18 (16), 4375-4384, 2012 | 250 | 2012 |
| Crenolanib is active against models of drug-resistant FLT3-ITD− positive acute myeloid leukemia EI Zimmerman, DC Turner, J Buaboonnam, S Hu, S Orwick, MS Roberts, ... Blood, The Journal of the American Society of Hematology 122 (22), 3607-3615, 2013 | 215 | 2013 |
| Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutations JK Randhawa, HM Kantarjian, G Borthakur, PA Thompson, M Konopleva, ... Blood 124 (21), 389, 2014 | 145 | 2014 |
| Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. JE Cortes, HM Kantarjian, TM Kadia, G Borthakur, M Konopleva, ... Journal of Clinical Oncology 34 (15_suppl), 7008-7008, 2016 | 108 | 2016 |
| Platelet-derived growth factor receptor-α regulates proliferation of gastrointestinal stromal tumor cells with mutations in KIT by stabilizing ETV1 Y Hayashi, MR Bardsley, Y Toyomasu, S Milosavljevic, GB Gajdos, ... Gastroenterology 149 (2), 420-432. e16, 2015 | 74 | 2015 |
| Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies W Zhang, C Gao, M Konopleva, Y Chen, RO Jacamo, G Borthakur, ... Clinical Cancer Research 20 (9), 2363-2374, 2014 | 62 | 2014 |
| Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia CM Cheney, DM Stephens, X Mo, S Rafiq, J Butchar, JM Flynn, JA Jones, ... MAbs 6 (3), 748-754, 2014 | 47 | 2014 |
| Characterization and targeting of platelet-derived growth factor receptor alpha (PDGFRA) in inflammatory breast cancer (IBC) M Joglekar-Javadekar, S Van Laere, M Bourne, M Moalwi, P Finetti, ... Neoplasia 19 (7), 564-573, 2017 | 44 | 2017 |
| Coarse-grained molecular dynamics simulation of DNA translocation in chemically modified nanopores A Ramachandran, Q Guo, SM Iqbal, Y Liu The Journal of Physical Chemistry B 115 (19), 6138-6148, 2011 | 34 | 2011 |
| Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations. M von Mehren, ED Tetzlaff, M Macaraeg, J Davis, V Agarwal, ... Journal of Clinical Oncology 34 (15_suppl), 11010-11010, 2016 | 33 | 2016 |
| Characterization of DNA-nanopore interactions by molecular dynamics A Ramachandran, Y Liu, W Asghar, SM Iqbal Am J Biomed Sci 1 (4), 344-351, 2009 | 32 | 2009 |
| Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML). R Collins, HM Kantarjian, MJ Levis, AE Perl, A Ramachandran, F Ravandi, ... Journal of Clinical Oncology 32 (15_suppl), 7027-7027, 2014 | 31 | 2014 |
| Crenolanib: a next generation FLT3 inhibitor A Galanis, T Rajkhowa, C Muralidhara, A Ramachandran, M Levis Cancer Research 72 (8_Supplement), 3660-3660, 2012 | 17 | 2012 |
| ONGOING CLINICAL TRIALS M Groves, J DeGroot, I Tremont, A Forman, S Kang, B Pei, W Julie, ... Neuro-oncology 13 (Suppl 3), iii85-iii91, 2011 | 16 | 2011 |
| The effect of crenolanib (CP-868596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors. MC Heinrich, D Griffith, A McKinley, A Presnell, A Ramachandran Journal of Clinical Oncology 29 (15_suppl), 10012-10012, 2011 | 14 | 2011 |
| Crenolanib, a novel type I, mutant specific inhibitor of class III receptor tyrosine kinases, preferentially binds to phosphorylated kinases A Ramachandran, H Marshall, V Jain Cancer Res 72 (8 supplement), 3683, 2012 | 13 | 2012 |
| First-in-pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine … C Wetmore, A Broniscer, D Turner, KD Wright, A Pai-Panandiker, LE Kun, ... Journal of Clinical Oncology 32 (15_suppl), 10064-10064, 2014 | 9 | 2014 |
| Crenolanib is a highly potent, selective, FLT3 TKI with activity against D835 mutations A Galanis, T Rajkhowa, C Muralidhara, A Ramachandran, MJ Levis Blood, The Journal of the American Society of Hematology 120 (21), 1341-1341, 2012 | 9 | 2012 |
| Full doses of crenolanib, a type I FLT3 inhibitor, can be safely administered in AML patients post allogeneic stem cell transplant R Collins, HM Kantarjian, F Ravandi, J Chen, M Macaraeg, V Urity, ... Blood 126 (23), 4359, 2015 | 8 | 2015 |